Please login to the form below

Not currently logged in
Email:
Password:

Keith Webber leaves FDA for Perrigo

Switches regulatory agency for biopharma company

Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process.

Perrigo will benefit from Webber's experience working with the US regulator, including most recently as acting director of the office of the FDA's pharmaceutical science in the Center for Drug Evaluation and Research (CDER), which over-the-counter and prescription drugs.

Prior to this, he oversaw regulation of generic medicines at the FDA as director of office of generic drug. This followed a period serving in several other leadership roles within the FDA.

The role marks a switch to the industry side of pharma for Webber, heading all the Perrigo's regulatory activities for both its consumer healthcare and prescription medicine business.

This includes holding responsibility for advancing the approval of drugs and providing guidance on regulatory strategy for products in development.

Perrigo's Chairman, president and CEO Joseph Papa commented that Webber “brings to us a wealth of strategic, scientific and regulatory experience from his years working with the FDA”.

27th September 2013

From: Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics